Blueprint Medicines Corp’s recent filing unveils that its CHIEF MEDICAL OFFICER Hewes L. Becker unloaded Company’s shares for reported $0.46 million on Mar 06 ’25. In the deal valued at $87.69 per share,5,232 shares were sold. As a result of this transaction, Hewes L. Becker now holds 30,419 shares worth roughly $2.65 million.
Then, Hewes L. Becker sold 4,863 shares, generating $431,834 in total proceeds. Upon selling the shares at $88.80, the CHIEF MEDICAL OFFICER now owns 35,651 shares.
Before that, Rossi Christina sold 6,495 shares. Blueprint Medicines Corp shares valued at $576,756 were divested by the CHIEF OPERATING OFFICER at a price of $88.80 per share. As a result of the transaction, Rossi Christina now holds 71,540 shares, worth roughly $6.23 million.
Scotiabank initiated its Blueprint Medicines Corp [BPMC] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $150. A number of analysts have revised their coverage, including JP Morgan’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. UBS began covering BPMC with “Neutral” recommendation on October 24, 2024. Stephens started covering the stock on May 14, 2024. It rated BPMC as “an Overweight”.
Price Performance Review of BPMC
On Friday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock fall -1.60% to $87.12. Over the last five days, the stock has lost -9.79%. Blueprint Medicines Corp shares have fallen nearly -0.11% since the year began. Nevertheless, the stocks have fallen -2.84% over the past one year. While a 52-week high of $121.90 was reached on 01/27/25, a 52-week low of $80.68 was recorded on 03/04/25. SMA at 50 days reached $98.98, while 200 days put it at $97.82.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 86.06, which if violated will result in even more drops to 85.01. On the upside, there is a resistance level at 89.09. A further resistance level may holdings at 91.06. The Relative Strength Index (RSI) on the 14-day chart is 34.23, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.90, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.66%. Stochastics %K at 21.73% indicates the stock is a holding.
